5443392025-01-012025-03-315443392025-03-315443392024-03-315443392024-04-012025-03-315443392025-01-012025-03-31in-capmkt:OtherExpenses1Member5443392024-04-012025-03-31in-capmkt:OtherExpenses1Member5443392025-01-012025-03-31in-capmkt:ReportableSegments1Member5443392025-01-012025-03-31in-capmkt:ReportableSegments2Member5443392025-01-012025-03-31in-capmkt:ReportableSegments3Member5443392024-04-012025-03-31in-capmkt:ReportableSegments1Member5443392024-04-012025-03-31in-capmkt:ReportableSegments2Member5443392024-04-012025-03-31in-capmkt:ReportableSegments3Member5443392025-01-012025-03-31in-capmkt:ReportableSegments1Member5443392025-01-012025-03-31in-capmkt:ReportableSegments2Member5443392025-01-012025-03-31in-capmkt:ReportableSegments3Member5443392024-04-012025-03-31in-capmkt:ReportableSegments1Member5443392024-04-012025-03-31in-capmkt:ReportableSegments2Member5443392024-04-012025-03-31in-capmkt:ReportableSegments3Member5443392025-01-012025-03-31in-capmkt:ReportableSegments1Member5443392025-03-31in-capmkt:ReportableSegments1Member5443392025-01-012025-03-31in-capmkt:ReportableSegments2Member5443392025-03-31in-capmkt:ReportableSegments2Member5443392025-01-012025-03-31in-capmkt:ReportableSegments3Member5443392025-03-31in-capmkt:ReportableSegments3Member5443392025-01-012025-03-31in-capmkt:ReportableSegments1Member5443392025-03-31in-capmkt:ReportableSegments1Member5443392025-01-012025-03-31in-capmkt:ReportableSegments2Member5443392025-03-31in-capmkt:ReportableSegments2Member5443392025-01-012025-03-31in-capmkt:ReportableSegments3Member5443392025-03-31in-capmkt:ReportableSegments3Member5443392025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15443392025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25443392024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15443392024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25443392025-01-012025-03-31AuditorDomain1iso4217:INRxbrli:pureiso4217:INRxbrli:shares544339LAXMIDENTLNOTLISTEDINE0WO601020Laxmi Dental LimitedMain BoardEquity2024-04-012025-03-312025-05-262025-05-21INRMillionsQuarterlyFourth quarterMulti segment2025-05-2617:00:002025-05-2623:55:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31AuditedConsolidated606680000163100006229900004105000092520000-465000024407000012570000429800001384500005669900005600000041000006010000091300001565000024780000035320000000743000042750000-56100003714000042820000-7000037190000-5000010992000020.790.78000.790.780.00050.01040.0758Note to the Consolidated Financial Results: <BR> <BR> 1 The audited consolidated financial results for the year ended 31 March 2025 has been prepared on the basis of the consolidated annual financial statements in accordance with Indian Accounting Standards as notified under the Companies Indian Accounting Standards Rules 2015 as amended specified under section 133 of the Companies Act, 2013 and in compliance with Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015 the Regulation as amended were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meeting held on 26 May <BR> 2025. The Statutory Auditors of the Company have expressed an unmodified opinion on the audited consolidated financial results for the year ended 31 March 2025. <BR> <BR> 2 The figures of the quarter ended 31 March 2025 are the balancing figures between the audited figures in respect of full financial year and the unaudited published year to date figures upto 31 December 2024 which were subject to limited review. <BR> <BR> 3 The figures of the quarter ended 31 March 2024 are the balancing figures between the audited figures in respect of full financial year General purpose consolidated financial statements of the group and the year to date figures upto 31 December 2023 based on the information compiled by the management in accordance with Ind AS and have not been subjected to review or audit by the statutory auditor or by any other auditor. <BR> <BR> Consolidated Segment wise Revenue Results Assets and Liabilities. <BR> <BR> The Chief Operational Decision Maker CODM monitors the operating results of its Business Segments separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on profit or loss and is measured consistently with profit or loss in the consolidated financial statements. Operating segments have been identified on the basis of the nature of products / services and have been identified as per the quantitative criteria specified in the Ind AS 108 which are described below <BR> <BR> Laboratory Business This segment comprises of Dental Prosthesis such as metal free crowns and bridges Porcelain Fused to Metal PFM Crowns and Bridges Dentures. <BR> <BR> Aligners Business This segment comprises of Dental Aligners Retainers Raw Materials for Aligners Sport Guards Night Guards Sleep Apnea Devices. <BR> <BR> Other Business This segment comprises of Dental distribution products used in Dental Laboratory Dental Clinical Services and Dental Educational Courses. <BR> <BR> Segment assets and liabilities The CODM does not monitor operating assets used by the operating segment. Therefore disclosures of segment assets liabilities and capital expenditure have not been given. <BR> <BR> 5 During the year ended 31 March 2025 the Company has converted the 0.0001% Compulsorily Convertible Preference Shares CCPS aggregating to 290597 preference shares of par value of Rs 400 each to 23922450 Equity Shares of Rs 2 each. <BR> <BR> 6 During the year the Board of Directors and Shareholders of the Company has approved the Employee Stock Option Plan 2024 ESOP 2024 for the employees of the Company and its subsidiary companies comprising of equity shares of the Company not exceeding 500000 equity shares of face value of Rs. 2 each. The company has granted 351672 equity shares of face value of Rs 2 each on 14 December 2024 to its eligible employees. <BR> <BR> 7 On 7 May 2024 the Holding Company sold one of its Investment properties at the sale consideration of Rs 101 million. The book value of the aforesaid Property as on the date of sale was Rs. 7.10 million. The Holding Company accounted for difference between the sale consideration and book value as gain on sale of Investment property amounting to Rs. 70.27 million net of tax Rs 23.64 million as an exceptional gain. Subsequent to the quarter and six month period ended 30 September 2024 the Holding Company has opted to avail benefit of section 115BAA and the corresponding revision of net tax effect has been considered in the exception items. <BR> <BR> During the year ended 31 March 2025 the Company split its 309060 equity shares of face value of Rs.10 each to 1545300 Equity Shares of face value of Rs 2 each. <BR> Further on approval of the Board of Directors and Shareholders the company issued 26270100 bonus shares 17:1 face value of Rs 2 each by capitalizing the free reserves. Basic and Diluted EPS disclosed after considering effect of bonus and split equity shares issued. <BR> <BR> 9 During the quarter and year ended 31 March 2025 the Company has completed an Initial Public Offer of 16309766 equity shares of face value of Rs. 2 each comprising of fresh issue of 3224299 equity shares at an issue price of Rs 428 per equity share aggregating to Rs. 1380 million and an offer for sale of 13085467 equity shares at an issue price of Rs 428 per equity share aggregating to Rs. 5600.58 million and listed on both Bombay Stock Exchange Limited BSE and National Stock Exchange NSE on 20 January 2025. The Company has received gross proceeds from fresh issue of Rs 1380.00 million against which Company has incurred an estimated issue related expenses net off tax of Rs 92.29 million. Out of the net proceeds which were unutilised as at 31 March 2025 Rs 950.33 million are temporarily invested in fixed deposits. <BR> <BR> On 16 August 2024 the Group entered into a Contract for Sale of division i.e. Alvy Dental Supply considering the carrying value as at 30 June 2024. The Group de- recognized the net carrying value of assets other than cash and cash equivalent of INR 17.76 millions as on date of sale i.e.30 June 2024 on completion of closure terms. During the year ended 31 March 2025 the said division has been sold out at the value at which the same was recognised. <BR> <BR> 11 Previous year period figures have been regrouped reclassified whenever necessary to confirm to current years classification. <BR> <BR> 12 The financial results of the Company are available on the Companys website www.laxmidentallimited.com and stock exchanges websites BSE www.bseindia.com and NSE www.nseindia.com where the shares of the Company are listed. <BR> <BR> <BR> 2024-04-012025-03-31AuditedConsolidated23910700003338000024244500003722700001945900005550000857680000539000001501900005422500002176430000248020000702700003182900002221000042330000645400000253750000-8090000-1000000-709000071680000318340000-5340000313000000317710000630000312340000660000109920000219754500006.26.19-0.14-0.146.066.050.00050.01040.0777Other Expenses138450000Other Expenses54225000041126000000940800002150000103840000026407000036791000010069000097609000018650000003667600009081800001854200001720000611100001523190000160870000187056000028466500001099200001975450000208537000016400002087010000106090000540000011149000034590000465200001926000007580000153100003052900003206000007042000039860000014569000012000000107500005670400007596400002846650000Laboratory Business384440000Aligners Business192180000Other Business47370000Laboratory Business1541620000Aligners Business808510000Other Business1494500006239900002499580000173100001085100006066800002391070000Laboratory Business83270000Aligners Business14350000Other Business-2360000Laboratory Business262220000Aligners Business149200000Other Business73100009526000041873000012570000539000002666000011680000056030000248030000Laboratory Business0Aligners Business0Other Business0000Laboratory Business0Aligners Business0Other Business0000Segment assets and liabilities <BR> <BR> The Chief Opcmtional Decision Maker does not monitor operating assets used by the operating segment. Therefore, disclosures of segment assets, liabilities and capital expenditure have not been given.5390000077450000-10374000000-42370000-426600000012314000000015019000005850000006960000-1520000001432000021900000-702700000002230000-809000014497000046326000000024940000043832000000210000000000763600001512400007540000150100000954000000000000000000143200000-216950000-2924200000013800000000386600000002038500003379700004690000005390000000110642000012523200003600001252680000-1590800001093600000Remeasurement gain of net defined benefit plan-7300000lncome tax effect on above1670000-5630000Remeasurement gain of net defined benefit plan-7600000lncome tax effect on above1900000-570000000-20000-360000-5610000-5340000AuditedtrueM S K A & Associatestrue2027-07-31